Evidence mapPaperPMID 33328161Full record

Trial reportBMJ open diabetes research & care2020

Circulating sex hormone binding globulin levels are modified with intensive lifestyle intervention, but their changes did not independently predict diabetes risk in the Diabetes Prevention Program.

Vanita R Aroda, Costas A Christophi, Sharon L Edelstein, Leigh Perreault, Catherine Kim, Sherita H Golden, Edward Horton, Kieren J Mather, DPP Research Group

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMJ open diabetes research & care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Vanita R ArodaMedStar Health Research Institute, Hyattsville, Maryland, USA varoda@bwh.harvard.edu.
Costas A ChristophiThe Biostatistics Center, The George Washington University Milken Institute of Public Health, Rockville, Maryland, USA.
Sharon L EdelsteinThe Biostatistics Center, The George Washington University Milken Institute of Public Health, Rockville, Maryland, USA.ORCID 0000-0001-8457-4404
Leigh PerreaultDepartment of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Catherine KimDepartments of Medicine, Obstetrics & Gynecology, and Epidemiology, University of Michigan, Ann Arbor, Michigan, USA.
Sherita H GoldenDivision of Endocrinology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-8854-4026
Edward HortonJoslin Diabetes Center, Boston, Massachusetts, USA.
Kieren J MatherIndiana University School of Medicine, Indianapolis, Indiana, USA.
DPP Research Group
Milken Institute · USBrigham and Women's Hospital · USIndiana University School of MedicineJohns Hopkins University · USJoslin Diabetes Center · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Michigan · US

Funding

PRIMARY PREVENTION TRIAL--DATA COORDINATING CENTERU01DK048489 · GEORGE WASHINGTON UNIVERSITY · 1994 to 2005
$23.7M
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · 1986 to 2025
$12.6M
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · UNIVERSITY OF COLORADO DENVER · 1995 to 2025
$7.7M
Pilot and Feasibility ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2022 to 2025
$4.9M
Post-DDP Follow-up StudyU01DK048413 · UNIVERSITY OF WASHINGTON · 1994 to 2005
$4.4M
TITLE OMITTEDU01DK048349 · YESHIVA UNIVERSITY · 1994 to 2005
$4.0M
PRIMARY PREVENTION TRIALU01DK048443 · UNIVERSITY OF SOUTHERN CALIFORNIA · 1994 to 2005
$4.0M
PRIMARY PREVENTION TRIAL (DPT-2)U01DK048397 · MASSACHUSETTS GENERAL HOSPITAL · 1994 to 2005
$3.8M
Post-DPP Follow-up StudyU01DK048485 · JOHNS HOPKINS UNIVERSITY · 1994 to 2005
$3.7M
NIDDM PRIMARY PREVENTION TRIALU01DK048412 · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 1994 to 2005
$3.6M
PRIMARY PREVENTION TRIAL (DPT-2)U01DK048339 · UNIVERSITY OF CALIFORNIA SAN DIEGO · 1994 to 2005
$3.6M
Post-DPP Follow-Up StudyU01DK048400 · WASHINGTON UNIVERSITY · 1994 to 2005
$3.6M
NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P30 DK048520NIDDK NIH HHS P30 DK079626NIDDK NIH HHS P30 DK097512NIDDK NIH HHS U01 DK048339NIDDK NIH HHS U01 DK048349NIDDK NIH HHS U01 DK048375NIDDK NIH HHS U01 DK048380NIDDK NIH HHS U01 DK048381NIDDK NIH HHS U01 DK048387NIDDK NIH HHS U01 DK048397NIDDK NIH HHS U01 DK048400NIDDK NIH HHS U01 DK048404NIDDK NIH HHS U01 DK048407NIDDK NIH HHS U01 DK048412NIDDK NIH HHS U01 DK048413NIDDK NIH HHS U01 DK048434NIDDK NIH HHS U01 DK048437NIDDK NIH HHS U01 DK048443NIDDK NIH HHS U01 DK048468NIDDK NIH HHS U01 DK048485NIDDK NIH HHS U01 DK048489NIDDK NIH HHS U01 DK048514
6 · The paper itself

Abstract

introductionSex hormone binding globulin (SHBG) levels are reported to be inversely associated with diabetes risk. It is unknown whether diabetes prevention interventions increase SHBG and whether resultant changes in SHBG affect diabetes risk. The purpose of this analysis was to determine whether intensive lifestyle intervention (ILS) or metformin changed circulating SHBG and if resultant changes influenced diabetes risk in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND

methodsThis is a secondary analysis from the DPP (1996-2001), a randomized trial of ILS or metformin versus placebo on diabetes risk over a mean follow-up of 3.2 years. The DPP was conducted across 27 academic study centers in the USA. Men, premenopausal and postmenopausal women without hormone use in the DPP were evaluated. The DPP included overweight/obese persons with elevated fasting glucose and impaired glucose tolerance. Main outcomes measures were changes in SHBG levels at 1 year and risk of diabetes over 3 years.

resultsILS resulted in significantly higher increases (postmenopausal women: p<0.01) or smaller decrements (men: p<0.05; premenopausal women: p<0.01) in SHBG compared with placebo or metformin. Changes in SHBG were primarily attributable to changes in adiposity. There were no consistent associations of change in SHBG with the risk of diabetes by treatment arm or participant group.

conclusionsLifestyle intervention may be associated with favorable changes in circulating SHBG, which is largely due to changes in adiposity. Changes in circulating SHBG do not independently predict reductions in diabetes incidence.

Indexed as

Diabetes Mellitus, Type 2Glucose IntoleranceMetforminFemaleHumansLife StyleMaleSex Hormone-Binding GlobulinMetforminSex Hormone-Binding Globulindiabetes mellitushormonelife styleprimary preventiontype 2

Identifiers

PMID33328161
PMCPMC7745696
OpenAlexW3112406500

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.